Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells

Endocrinology

Volumn 150, Issue 10, 2009, Pages 4473-4483

  Amiry, Naeem ^a   Kong, Xiangjun ^c   Muniraj, Nethaji ^a   Kannan, Nagarajan ^a   Grandison, Prudence M ^a   Lin, Juan ^c   Yang, Yulu ^c   Vouyovitch, Cécile M ^d   Borges, Sahra ^d   Perry, Jo K ^a   Mertani, Hichem C ^d   Zhu, Tao ^c   Liu, Dongxu ^a   Lobie, Peter E ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN PS2; TREFOIL FACTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER REGRESSION; CANCER SURGERY; CARCINOGENICITY; CARCINOMA CELL; CELL COUNT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; RNA INTERFERENCE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 70349333349     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0066     Document Type: Article

References (70)

1. Taupin D, Podolsky DK 2003 Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 4:721-732 (Pubitemid 37082187)
2. Thim L, May FEB 2005 Structure of mammalian trefoil factors and functional insights. Cell Mol Life Sci 62:2956-2973 (Pubitemid 43004748)
3. Clyne M, Dillon P, Daly S, O'Kennedy R, May FE, Westley BR, Drumm B 2004 Helicobacter pylori interacts with the human single-domain trefoil protein TFF1. Proc Natl Acad Sci USA 101:7409-7414
4. Perry JK, Kannan N, Grandison PM, Mitchell MD, Lobie PE 2008 Are trefoil factors oncogenic? Trends Endocrinol Metab 19:74-81
5. Rodrigues S, Rodrigue CM, Attoub S, Fléjou JF, Bruyneel E, Bracke M, Emami S, Gespach C 2006 Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells. Oncogene 25:6628-6636 (Pubitemid 44646190)
6. Regalo G, Wright NA, Machado JC 2005 Trefoil factors: from ulceration to neoplasia. Cell Mol Life Sci 62:2910-2915
7. Prasad NB, Biankin AV, Fukushima N, Maitra A, Dhara S, Elkahloun AG, Hruban RH, Goggins M, Leach SD 2005 Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 65:1619-1626 (Pubitemid 40478583)
8. Emami S, Rodrigues S, Rodrigue CM, Le Floch N, Rivat C, Attoub S, Bruyneel E, Gespach C 2004 Trefoil factor family (TFF) peptides and cancer progression. Peptides 25:885-898 (Pubitemid 38721356)
9. Vestergaard EM, Borre M, Poulsen SS, Nexø E, Tørring N 2006 Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res 12:807-812 (Pubitemid 43259861)
10. Ribieras S, Tomasetto C, Rio MC 1998 The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta 1378:F61-F77
11. Rodrigues S, Attoub S, Nguyen QD, Bruyneel E, Rodrigue CM, Westley BR, May FE, Thim L, Mareel M, Emami S, Gespach C 2003 Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells. Oncogene 22:4488-4497 (Pubitemid 36920692)
12. Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, Bruyneel E, Westley BR, May FE, Thim L, Mareel M, Gespach C, Emami S 2003 Trefoil peptides as proangiogenic factors in vivo and in vitro: Implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 17:7-16 (Pubitemid 36119830)
13. Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B, May F, Flatau G, Mareel M, Gespach C, Emami S 2001 Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J 15:1517-1528 (Pubitemid 32673381)
14. Spruck C, Sun D, Fiegl H, Marth C, Mueller-Holzner E, Goebel G, Widschwendter M, Reed SI 2006 Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res 66:7355-7360 (Pubitemid 44197719)
15. Ceccarelli C, Piazzi G, Paterini P, Pantaleo MA, Taffurelli M, Santini D, Martinelli GN, Biasco G 2005 Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and tumour spreading. Ann Oncol 16:iv74 -iv79 (Pubitemid 43084950)
16. Chalbos D, Westley B, May F, Alibert C, Rochefort H 1986 Cloning of cDNA sequences of a progestin-regulated mRNA from MCF7 human breast cancer cells. Nucleic Acids Res 14:965-982 (Pubitemid 16136143)
17. Jeltsch JM, Roberts M, Schatz C, Garnier JM, Brown AM, Chambon P 1987 Structure of the human oestrogen-responsive gene pS2. Nucleic Acids Res 15:1401-1414 (Pubitemid 17010426)
18. Henry JA, Nicholson S, Hennessy C, Lennard TW, May FE, Westley BR 1990 Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br J Cancer 61:32-38 (Pubitemid 20043540)
19. Poulsom R, Hanby AM, Lalani EN, Hauser F, Hoffmann W, Stamp GWH 1997 Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol 183:30-38 (Pubitemid 27368523)
20. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR 2001 High expression of the trefoil protein TFF1 in interval breast cancers. Am J Pathol 159:215-221 (Pubitemid 33704206)
21. Gillesby BE, Zacharewski TR 1999 pS2 (TFF1) levels in human breast cancer tumor samples: Correlation with clinical and histological prognostic markers. Breast Cancer Res Treat 56:253-265
22. Soubeyran I, Quénel N, Coindre JM, Bonichon F, Durand M, Wafflart J, Mauriac L 1996 pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer 74:1120-1125 (Pubitemid 26333917)
23. Speiser P, Stolzlechner J, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeilliger R 1994 pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Anticancer Res 14:2125-2130
24. Liu DX, Lobie PE 2007 Transcriptional activation of p53 by Pitx1. Cell Death Differ 14:1893-1907
25. Pandey V, Perry JK, Mohankumar KM, Kong XJ, Liu SM, Wu ZS, Mitchell MD, Zhu T, Lobie PE 2008 Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 149:3909-3919
26. Frankel S, Sohn R, Leinwand L 1991 The use of sarkosyl in generating soluble protein after bacterial expression. Proc Natl Acad Sci USA 88:1192-1196 (Pubitemid 21916191)
27. Thiele D, Karo M, Krauss H 1992 Monoclonal antibody based capture ELISA/ELIFA for detection of Coxiella burnetii in clinical specimens. Eur J Epidemiol 8:568-574
28. Zhu Z, Mukhina S, Zhu T, Mertani HC, Lee KO, Lobie PE 2005 p44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis. Oncogene 24:3774-3785 (Pubitemid 40826876)
29. Rahnama F, Shafiei F, Gluckman PD, Mitchell MD, Lobie PE 2006 Epigenetic regulation of human trophoblastic cell migration and invasion. Endocrinology 147:5275-5283 (Pubitemid 44801523)
30. van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MM 1994 A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells. J Immunol Methods 174:311-320
31. Zhu T, Starling-Emerald B, Zhang X, Lee KO, Gluckman PD, Mertani HC, Lobie PE 2005 Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res 65:317-324 (Pubitemid 40070824)
32. Zhang X, Zhu T, Chen Y, Mertani HC, Lee KO, Lobie PE 2003 Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J Biol Chem 278:7580-7590 (Pubitemid 36800766)
33. Harari D, Yarden Y 2000 Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19:6102-6114 (Pubitemid 32059460)
34. Milanezi F, Carvalho S, Schmitt FC 2008 EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Exp Rev Mol Diagn 8:417-434 (Pubitemid 351962088)
35. Dean-Colomb W, Esteva FJ 2008 Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer 44:2806-2812
36. Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ 2008 MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 111:497-504
37. Callus BA, Moujallad DM, Silke J, Gerl R, Jabbour AM, Ekert PG, Vaux DL 2008 Triggering of apoptosis bypumais determined by the threshold set by prosurvival Bcl-2 family proteins. J Mol Biol 384:313-323
38. Yilmaz M, Christofori G, Lehembre F 2007 Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 13:535-541 (Pubitemid 350123764)
39. Wolf K, Friedl P 2006 Molecular mechanisms of cancer cell invasion and plasticity. Br J Dermatol 154(Suppl 1):11-15
40. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE 2004 Phenotypic conversion ofhumanmammarycarcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA 101:15166-15171 (Pubitemid 39391736)
41. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y, Khanna R, Tamburini P, Swaroop A, Kandpal RP 2006 Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 25:2328-2338
42. Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, Liang SH, Gillett CE, Campisi J, Desprez PY 2000 A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res 60:1332-1340 (Pubitemid 30152003)
43. Yang TH, Chen CT, Wang CP, Lou PJ 2007 Photodynamic therapy suppresses the migration and invasion of head and neck cancer cells in vitro. Oral Oncol 43:358-365
44. Orecchia S, Schillaci F, Salvio M, Libener R, Betta PG 2004 Aberrant E-cadherin and γ-catenin expression in malignant mesothelioma and its diagnostic and biological relevance. Lung Cancer 45(Suppl 1):S37-S43 (Pubitemid 38917112)
45. Kowalski PJ, Rubin MA, Kleer CG 2003 E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 5:R217-R222
46. Bukholm IK, Nesland JM, Kåresen R, Jacobsen U, Børresen-Dale AL 1998 E-cadherin and α-, β-, and γ-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 185: 262-266 (Pubitemid 28320047)
47. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M 2007 Vimentin and epithelial-mesenchymal transition in human breast cancer: observations in vitro and in vivo. Cells Tissues Organs 185:191-203 (Pubitemid 46957486)
48. Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, Black JD, Tan D, Khoury T 2007 Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol 14:3527-3533 (Pubitemid 350160113)
49. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Leffall LD 2005 Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 11:481-483 (Pubitemid 40685969)
50. Balduyck M, Zerimech F, Gouyer V, Lemaire R, Hemon B, Grard G, Thiebaut C, Lemaire V, Dacquembronne E, Duhem T, Lebrun A, Dejonghe MJ, Huet G 2000 Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis 18:171-178
51. Henry JA, Piggott NH, Mallick UK, Nicholson S, Farndon JR, Westley BR, May FEB 1991 pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 63:615-622
52. Rio MC, Bellocq JP, Foekens J, Chenard MP, Koehl C, Gairard B, Renaud R, Chambon P 1991 Expression of the pS2 protein in hormone-dependent breast cancers. Contracept Fertil Sexual 19:35-37 (French)
53. Rio MC, Bellocq JP, Foekens J, Chenard MP, Koehl C, Gairard B, Renaud R, Chambon P 1990 pS2 protein expression in hormone-dependent breast cancers. Bull Cancer 77(Suppl 1):S135-S139
54. Rio MC, Chambon P 1990 The pS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells 2:269-274 (Pubitemid 20290109)
55. Corte MD, Tamargo F, Alvarez A, Rodríguez JC, Vázquez J, Sánchez R, Lamelas ML, González LO, Allende MT, García-Muñiz JL, Fueyo A, Vizoso F 2006 Cytosolic levels of TFF1/pS2 in breast cancer: their relationship with clinical-pathological parameters and their prognostic significance. Breast Cancer Res Treat 96:63-72
56. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P, Thor AD 1991 pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 51:624-628
57. Chenard MP, Tomasetto C, Bellocq JP, Rio MC 2004 Urinary pS2/TFF1 levels in the management of hormonodependent breast carcinomas. Peptides 25:737-743 (Pubitemid 38721338)
58. Girdler F, Browell DA, Brotherick I, Cunliffe WJ, Higgs MJ, Hemming D, Lennard TW, Young JR, Shenton BK 2001 Three weeks of tamoxifen treatment alters the expression of ERα, ERβ and pS2. Breast Cancer Res Treat 69:293
59. Mikhitarian K, Gillanders WE, Almeida JS, Hebert Martin R, Varela JC, Metcalf JS, Cole DJ, Mitas M 2005 An innovative microarray strategy identities informative molecular markers for the detection of micrometastatic breast cancer. Clin Cancer Res 11:3697-3704 (Pubitemid 40685586)
60. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA 2006 Genes associated with breast cancer metastatic to bone. J Clin Oncol 24:2261-2267 (Pubitemid 46630655)
61. Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, Hart AA, Rodenhuis S, van 't Veer LJ 2002 Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 8:1871-1877 (Pubitemid 34633748)
62. Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van't Veer LJ 2003 Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 88:1091-1094
63. Bossenmeyer-Pourié C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L, Tomasetto C, Rio MC 2002 The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol 157:761-770 (Pubitemid 34847814)
64. Playford RJ, Marchbank T, Goodlad RA, Chinery RA, Poulsom R, Hanby AM, Wright NA 1996 Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA 93:2137-2142 (Pubitemid 26079894)
65. Park K, Kwak K, Kim J, Lim S, Han S 2005 c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol 36:634-639 (Pubitemid 40922569)
66. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH 2004 AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene 23:8238-8246 (Pubitemid 39531835)
67. Lu A, Zhang F, Gupta A, Liu J 2002 Blockade of AP1 transactivation abrogates the abnormal expression of breast cancer-specific gene 1 in breast cancer cells. J Biol Chem 277:31364-31372 (Pubitemid 34968935)
68. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TW, Horne CH 1995 Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:885-891
69. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M, Stacey DW 2005 Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 24:2599-2612 (Pubitemid 40593088)
70. Stacey DW 2003 Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 15:158-163